Share on StockTwits

Equities researchers at Leerink Swann increased their target price on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from $389.00 to $436.00 in a research report issued on Tuesday. The firm currently has an “outperform” rating on the stock. Leerink Swann’s price objective indicates a potential upside of 24.41% from the company’s current price.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein unloaded 2,000 shares of the stock on the open market in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $350.31, for a total value of $700,620.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 350.455 on Tuesday. Regeneron Pharmaceuticals has a 52-week low of $245.99 and a 52-week high of $354.79. The stock’s 50-day moving average is $328.2 and its 200-day moving average is $312.7. The company has a market cap of $35.182 billion and a P/E ratio of 99.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $2.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $2.30 by $0.17. The company had revenue of $666.00 million for the quarter, compared to the consensus estimate of $647.99 million. During the same quarter last year, the company posted $1.73 earnings per share. Regeneron Pharmaceuticals’s revenue was up 45.4% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals will post $10.15 earnings per share for the current fiscal year.

REGN has been the subject of a number of other recent research reports. Analysts at Zacks downgraded shares of Regeneron Pharmaceuticals from an “outperform” rating to an “underperform” rating in a research note on Tuesday, August 26th. They now have a $316.00 price target on the stock. Separately, analysts at RBC Capital raised their price target on shares of Regeneron Pharmaceuticals from $349.00 to $373.00 in a research note on Wednesday, August 6th. They now have an “outperform” rating on the stock. Finally, analysts at Roth Capital reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, August 5th. One research analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $352.11.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.